AURX

Nuo Therapeutics Inc

AURX, USA

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.

https://www.nuot.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
AURX
stock
AURX

Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew Yahoo Finance

Read more →

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-107.90

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

78.79 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-47.79 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

37.23 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.00% of the total shares of Nuo Therapeutics Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0113

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(6)
Growth
Moderate Growth(6)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Moderate Quality(4.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.